# IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

> **NCT07672483** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 95 (estimated)

## Conditions studied

- Relapsed Solid Tumor Malignancies
- Refractory Solid Tumor Malignancies

## Interventions

- **BIOLOGICAL:** IL-12 GEMys
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT07672483
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-14
- **Primary completion:** 2028-01-15
- **Final completion:** 2029-01-15
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672483, "IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07672483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*